Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (179)	9/20/2007 6:20:43 PM
From: Archie Meeties	Read Replies (2) \| Respond to of 269

Your take is that the CK explanation was the result of a post hoc analysis? I don't think blinding should have included blinding of CK results as that is a measure of methods, not results. If CK data was blinded then somebody botched the design. If it wasn't then even a casual look at the data should have suggested something was wrong with drug delivery. There no magic in the whole im/ck stuff...you traumatize muscle when you inject into it and so ck leaks out.

To: scaram(o)uche who wrote (179)	9/20/2007 10:01:07 PM
From: tom pope	Respond to of 269

If it's data mining they've found one hell of a vein. It's not like they stumbled on a subpopulation of club footed Caucasian males under the age of forty and yelled Eureka! This doesn't excuse their incompetence in the long needle/short needle gaffe, as Tuck put it.